Professor Li Min, Executive Associate Dean of Chinese Medicine at HKBU, has been appointed as the Ma Pak Leung Endowed Professor in Innovative Neuromedicine, commencing in February 2024. The endowed professorship was established with the funding support from Ma Pak Leung Company Limited with the aim of recognising the accomplishments of academics in the research and development of neuromedicine.  

A faculty member of HKBU’s School of Chinese Medicine (SCM) since 2011, Professor Li is a distinguished scholar, clinical expert and educator whose research interest focuses on elucidating the pathogenesis of neurodegenerative diseases, including Parkinson's disease (PD), Alzheimer's disease (AD) and vascular dementia (VD) as well as cardio-cerebrovascular disease and related new drug discovery.  

Professor Li’s leadership of the Mr. & Mrs. Ko Chi Ming Centre for Parkinson’s Disease Research at SCM has been pivotal in securing approximately HK$36 million in funding for 16 research projects. These projects are not only a beacon of hope for patients, but also a source of inspiration for the next generation of students and researchers that Professor Li has tirelessly mentored.  

Professor Li is ranked as the world’s top 2% of most-cited scientists 2023 by Stanford University. Over the years, she has presented and published over 400 papers about research and clinical findings on neurodegenerative diseases in internationally-renowned journals, professional books and international conferences. As of December 2023, Professor Li has been awarded over 20 patents related to the treatment of AD and PD.  

Please click here for more information about Professor Li’s profile.